'Believe in science': EU kicks off COVID-19 vaccine campaign

[Image]( EMAIL}/redirect SUNDAY, DECEMBER 27, 2020 | NICOLE WINFIELD, ASSOCIATED PRESS ROME (AP) — Doctors, nurses and the elderly rolled up their sleeves across the European Union to receive the first doses of the coronavirus vaccine Sunday in a symbolic show of unity and moment of hope for a continent confronting its worst health care crisis in a century. Even though a few countries gave out doses a day early, the coordinated rollout for the 27-nation bloc was aimed at projecting a unified message that the vaccine was safe and Europe’s best chance to emerge from the pandemic and the economic devastation caused by months of lockdown. For health care workers who have been battling the virus with only masks and shields to protect themselves, the vaccines represented an emotional relief as well as a public chance to urge Europe's 450 million people to get the shots for their own health and that of others. “Today I’m here as a citizen, but most of all as a nurse, to represent my category and all the health workers who choose to believe in science,” said Claudia Alivernini, 29, the first person to be inoculated at the Spallanzani infectious disease hospital in Rome. EMAIL}/redirect EMAIL}/redirect Austrian Chancellor Sebastian Kurz called the vaccine, which was developed in record time, a “game-changer.” “We know that today is not the end of the pandemic, but it is the beginning of the victory,” he said. Italian virus czar Domenico Arcuri said it was significant that Italy’s first doses were administered at Spallanzani, where a Chinese couple visiting from Wuhan tested positive in January and became Italy’s first confirmed cases. Within weeks, northern Lombardy became the epicenter of the outbreak in Europe and a cautionary tale of what happens when even wealthy regions find themselves unprepared for a pandemic. Lombardy still accounts for around a third of the dead in Italy, which has the continent’s worst confirmed virus death toll at nearly 72,000. EMAIL}/redirect EMAIL}/redirect “Today is a beautiful, symbolic day: All the citizens of Europe together are starting to get their vaccinations, the first ray of light after a long night,” Arcuri told reporters. But he cautioned: “We all have to continue to be prudent, cautious and responsible. We still have a long road ahead, but finally we see a bit of light.” The vaccine developed by Germany’s BioNTech and American drugmaker Pfizer started arriving in super-cold containers at EU hospitals on Friday from a factory in Belgium. Each country was only getting a fraction of the doses needed — fewer than 10,000 in the first batches — with the bigger rollout expected in January when more vaccines become available. All those getting shots Sunday have to come back for a second dose in three weeks. Ursula von der Leyen, head of the European Union’s Executive Commission, said with additional vaccines in development, the EU will have more shots than necessary and could share its surplus with the western Balkans and Africa. “Europe is well positioned,” she said. In the Los Olmos nursing home in the Spanish city of Guadalajara, northeast of Madrid, 96-year-old resident Araceli Hidalgo and a caregiver were the first Spaniards to receive the vaccine. “Let’s see if we can all behave and make this virus go away,” Hidalgo said. The Los Olmos home suffered two confirmed COVID-19 deaths and another 11 deaths among residents with symptoms who were never tested. The Czech Republic was spared the worst of the pandemic in the spring only to see its health care system near collapse in the fall. In Prague, Czech Prime Minister Andrej Babis received his shot at dawn Sunday and asserted: “There’s nothing to worry about.” Sitting next to him was World War II veteran Emilie Repikova, who also received a shot. Altogether, the EU’s 27 nations have recorded at least 16 million coronavirus infections and more than 336,000 deaths — huge numbers that experts say still understate the true toll of the pandemic due to missed cases and limited testing. The vaccination campaign should ease frustrations that were building up, especially in Germany, as Britain, Canada and the United States kicked off their inoculation programs with the same vaccine weeks earlier. As it turned out, some EU immunizations began a day early in Germany, Hungary and Slovakia. The operator of a German nursing home where dozens were vaccinated Saturday, including a 101-year-old woman, said “every day that we wait is one day too many.” In France, where many question the safety of vaccines, the French government has been cautious in its messaging and keen to ensure that it is not seen as forcing vaccinations on the public. France’s first vaccination at a nursing home in a poor area outside of Paris on Sunday was not broadcast on live television as it was elsewhere in Europe and no government ministers attended. “We didn’t need to convince her. She said ‘yes, I’m ready for anything to avoid getting this disease,’” said Dr. Samir Tine, head of geriatric services for the Sevran nursing home where France’s first shot went to 78-year-old Mauricette. “It’s an important day,” Tine said. “We are very eager to have a new weapon at our disposal and we are very eager to rediscover our normal lives.” Among the politicians who got shots Sunday to promote a wider acceptance of vaccinations was Bulgarian Health Minister Kostadin Angelov. “I can’t wait to see my 70-year-old father without fear that I could infect him,” Angelov said. After he got his shot, Greek Prime Minister Kyriakos Mitsotakis declared Sunday “a great day for science and the European Union." “We hope that, with time, even those of our fellow citizens who are suspicious of vaccination will be convinced it is the right thing to do," he said. Meanwhile, a new virus variant that has been spreading rapidly around London and southern England has now been detected in France, Italy, Spain, Canada and Japan. The new variant, which British authorities said is much more easily transmitted, has prompted many countries to restrict travel from Britain. Japan announced it would temporarily ban all non-resident foreigners from entering through Jan. 31 as a precaution against the U.K.’s new variant. Germany’s BioNTech has said it’s confident that its vaccine works against the new U.K. variant, but added that further studies are needed. The European Medicines Agency on Jan. 6 will consider approving another vaccine made by Moderna, which is already being used in the United States. Dr. Annalisa Malara, who diagnosed Italy's first domestic case on Feb. 20 that confirmed Europe's outbreak was underway, was on hand at her hospital in Codogno to encourage all Italians to get the shot. “Today we close the circle a bit that was opened on Feb. 20," she said. ___ AP journalists from around Europe contributed to this report. ___ EMAIL}/redirect EMAIL}/redirect © 2020 PTE.la PTE, LLC (publisher of PTE.la) is NOT registered as an investment adviser nor a broker/dealer with either the U. S. Securities & Exchange Commission or any state securities regulatory authority. Users of this website are advised that all information presented on this website is solely for informational purposes, is not intended to be used as a personalized investment recommendation, and is not attuned to any specific portfolio or to any user's particular investment needs or objectives. Past performance is NOT indicative of future results. Furthermore, such information is not to be construed as an offer to sell or the solicitation of an offer to buy, nor is it to be construed as a recommendation to buy, hold or sell (short or otherwise) any security. All users of this website must determine for themselves what specific investments to make or not make and are urged to consult with their own independent financial advisors with respect to any investment decision. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. All opinions, analyses and information included on this website are based on sources believed to be reliable and written in good faith, but should be independently verified, and no representation or warranty of any kind, express or implied, is made, including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. In addition, we undertake no responsibility to notify such opinions, analyses or information or to keep such opinions, analyses or information current. Also be aware that owners, employees and writers of and for PTE, LLC may have long or short positions in securities that may be discussed on this website or newsletter. Past results are not indicative of future profits. This table is accurate, though not every trade is represented. Profits and losses reported are simulated figures from virtual simulated portfolios. We are engaged in the business of advertising and promoting companies for monetary compensation. All content in our releases is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Neither the information presented nor any statement or expression of opinion, or any other matter herein, directly or indirectly constitutes a solicitation of the purchase or sale of any securities. PTE.la’s sponsored advertisements do not purport to provide an analysis of any company’s financial position, operations or prospects and this is not to be construed as are commendation by PTE.la or an offer or solicitation to buy or sell any security. Neither the owner of PTE.la nor any of its members, officers, directors, contractors or employees is licensed broker-dealers, account representatives, market makers, investment bankers, investment advisors, analyst or underwriters. Investing in securities, including the securities of those companies profiled or discussed on this website is for individuals tolerant of high risks. Viewers should always consult with alicensed securities professional before purchasing or selling any securities of companies profiled or discussed in our releases. It is possible that a viewer’s entire investment may be lost or impaired due to the speculative nature of the companies profiled. Remember, never invest in any security of a company profiled or discussed in a release or on our website unless you can afford to lose your entire investment. Also, investing in micro-cap securities is highly speculative and carries an extremely high degree of risk. To review our complete disclaimer and additional information, please visit . PTE.la makes no recommendation that the securities of the companies profiled or discussed in our releases or on our website should be purchased, sold or held by investors. PTE.la is owned and operated by PTE LLC. PTE LLC has not been compensated for this specific email, we do have advertisements in this email that we get paid if you click one of the ads (we have not investigated any of the advertisements). Any compensation received by PTE LLC constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. A third party of PTE LLC may have shares and may liquidate, which may negatively affect the stock price. PTE LLC affiliates may at any time have a position in the securities mentioned herein and may increase or decrease such positions without notice which will negatively affect the market. Some of the content in this release contains forward - looking information within the meaning of Section 27 A of the Securities Act of 1 9 9 3 and Section 21 E of the Securities Exchange Act of 1 9 3 4 including statements regarding expected continual growth of the profiled company and the value of its securities. In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 it is hereby noted that statements contained herein that look forward in time which include everything other than historical information, involve risk and uncertainties that may affect a company's actual results of operation. A company's actual performance could greatly differ from those described in any forward - looking statements or announcements mentioned in this release. Factors that should be considered that could cause actual results to differ include: the size and growth of the market for the company's products; the company's ability to fund its capital requirements in the near term and in the long term; pricing pressures; unforeseen and/or unexpected circumstances in happenings; etc. and the risk factors and other factors set forth in the company’s filings with the Securities and Exchange Commission. However, acompany’s past performance does not guarantee future results. Generally, the information regarding a company profiled is provided from public sources which we believe to be reliable but is not guaranteed by us as being accurate. Further specific financial information, filings and disclosures as well as general investor information about the profiled company, advice to investors and other investor resources are available at the Securities and Exchange Commission (“SEC”) website www.sec.gov and the Financial Industry Regulatory Authority (“FINRA”) website at www.finra.org. Any investment should be made only after consulting with a qualified investment advisor and reviewing the publicly available financial statement and other information about the company profiled and verifying that the investment is appropriate and suitable. PTE.la makes no representations, warranties or guarantees as to the accuracy or completeness of the information provided or discussed. Viewers should not rely solely on the information obtained in this release or on our website. PTE Team 9 Downing street Newark NJ 07105 USA [Unsubscribe]( [Change subscriber options](